An exploratory analysis of patients with stage II-IIIA, according to PD-L1 expression, reported that the benefit in DFS was mainly driven by tumors with high PD-L1 expression ≥50% (HR 0.43; 95% CI: 0.23–0.68) with no DFS benefit for NSCLC with intermediate PD-L1 expression 1–49% (HR: 0.87; 95% CI: 0.60–1.26) [31]. Here, CD274 is linked to non-small cell lung carcinoma.